Pituitary

pp 1–11 | Cite as

Cognitive-behavioral therapy improves the quality of life of patients with acromegaly

  • Lia Silvia Kunzler
  • Luciana Ansaneli Naves
  • Luiz Augusto Casulari
Article

Abstract

Background

The delayed diagnosis, altered body image, and clinical complications associated with acromegaly impair quality of life.

Purpose

To assess the efficacy of the cognitive-behavioral therapy (CBT) technique “Think Healthy” to increase the quality of life of patients with acromegaly.

Methods

This non-randomized clinical trial examined ten patients with acromegaly (nine women and one man; mean age, 55.5 ± 8.4 years) from a convenience sample who received CBT. The intervention included nine weekly group therapy sessions. The quality of life questionnaire the 36-Item Short Form Survey (SF-36) and the Beck Depression Inventory (BDI) were administered during the pre- and post-intervention phases. The Wilcoxon signed-rank test was performed to assess the occurrence of significant differences.

Results

According to the SF-36, the general health domain significantly improved (d′  = − 0.264; p = 0.031). The mental health domain improved considerably (d′  = − 1.123; p = 0.012). Physical functioning showed a non-significant trend toward improvement (d′  = − 0.802; p = 0.078), although four of the five patients who showed floor effects improved and remained at this level. Regarding emotional well-being, five patients showed floor effects and four improved, and the condition did not change among any of the four patients who showed ceiling effects. No significant changes were found with regard to the other domains. No significant differences in the BDI were found before or after the intervention.

Conclusion

The technique presented herein effectively improved the quality of life of patients with acromegaly with different levels of disease activity, type, and treatment time.

Keywords

Acromegaly Quality of life SF-36 Depression Cognitive-behavioral therapy 

Notes

Acknowledgements

We thank Dr. Luis Augusto Dias for his critical review of this manuscript. We also thank Iago Renato Peixoto, Armindo Jreige Junior, Isabella Araujo, Débora Maria de C. Saraiva, and Vitoria Espindola L. Borges, medical students at the University of Brasília. This study was conducted at the neuroendocrinology outpatient clinic of the University Hospital of Brasília.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Vilar L, Vilar CF, Lyra R, Lyra R, Naves LA (2017) Acromegaly: clinical features at diagnosis. Pituitary 20:22–32CrossRefPubMedGoogle Scholar
  2. 2.
    Siegel S, Streetz-van der Werf C, Schott JS, Nolte K, Karges W, Kreitschmann-Andermahr I (2013) Diagnostic delay is associated with psychosocial impairment in acromegaly. Pituitary 16:507–514CrossRefPubMedGoogle Scholar
  3. 3.
    Dantas RAE, Passos KE, Porto LB, Zakir JCO, Reis MC, Naves LA (2013) Physical activities in daily life and physical functioning compared to disease activity control in acromegalic patients: impact in self-reported quality of life. Arq Bras Endocrinol Metabol 57(7):550–557CrossRefPubMedGoogle Scholar
  4. 4.
    Abreu A, Tovar AP, Castellanos R, Valenzuela A, Giraldo CMG, Pinedo AC, Guerrero DP, Barrera CAB, Franco HI, Ribeiro-Oliveira A, Vilar L, Jallad RS, Duarte FG, Gadelha M, Boguszewski CL, Abucham J, Naves LA, Musolino NRC, de Faria MEJ, Rossato C, Bronstein MD (2016) Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary 19(4):448–457CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Fujio S, Tokimura H, Hirano H, Hanaya R, Kubo F, Yunoue S, Bohara M, Kinoshita Y, Tominaga A, Arimura H, Arita K (2013) Severe growth hormone deficiency is rare in surgically-cured acromegalics. Pituitary 16:326–332PubMedGoogle Scholar
  6. 6.
    Szcześniak D, Jawiarczyk-Przybyłowska A, Rymaszewska J (2015) The quality of life and psychological, social and cognitive functioning of patients with acromegaly. Adv Clin Exp Med 24(1):167–172CrossRefPubMedGoogle Scholar
  7. 7.
    Kepicoglu H, Hatipoglu E, Bulut I, Darici E, Hizli N, Kadioglu P (2014) Impact of treatment satisfaction on quality of life of patients with acromegaly. Pituitary 17(6):557–563CrossRefPubMedGoogle Scholar
  8. 8.
    Tiemensma J, Kaptein AA, Pereira AM, Smit JWA, Romijn JA, Biermasz NR (2011) Affected illness perceptions and the association with impaired quality of life in patients with long-term remission of acromegaly. J Clin Endocrinol Metab 96(11):3550–3558CrossRefPubMedGoogle Scholar
  9. 9.
    Milian M, Honegger J, Gerlach C, Psaras T (2013) Health-related quality of life and psychiatric symptoms improve effectively within a short time in patients surgically treated for pituitary tumors—a longitudinal study of 106 patients. Acta Neurochir 155(9):1637–1645CrossRefPubMedGoogle Scholar
  10. 10.
    Vandeva S, Yaneva M, Natchev E, Elenkova A, Kalinov K, Zacharieva S (2015) Disease control and treatment modalities have impact on quality of life in acromegaly evaluated by Acromegaly Quality of Life (AcroQoL) Questionnaire. Endocrine 49(3):774–782CrossRefPubMedGoogle Scholar
  11. 11.
    Van Der Klaauw AA, Biermasz NR, Hoftijzer HC, Pereira AM, Romijn JA (2008) Previous radiotherapy negatively influences quality of life during 4 years of follow up in patients cured from acromegaly. Clin Endocrinol 69(1):123–128CrossRefGoogle Scholar
  12. 12.
    Anagnostis P, Efstathiadou ZA, Charizopoulou M, Selalmatzidou D, Karathanasi E, Poulasouchidou M, Kita M (2014) Psychological profile and quality of life in patients with acromegaly in Greece. Is there any difference with other chronic diseases? Endocrine 47(2):564–571CrossRefPubMedGoogle Scholar
  13. 13.
    Miller A, Doll H, David J, Wass J (2008) Impact of musculoskeletal disease on quality of life in long-standing acromegaly. Eur J Endocrinol 158(5):587–593CrossRefPubMedGoogle Scholar
  14. 14.
    Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F (2005) Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 90(5):2731–2739CrossRefPubMedGoogle Scholar
  15. 15.
    Geraedts VJ, Andela CD, Stalla GK, Pereira AM, van Furth WR, Sievers C, Biermasz NR (2017) Predictors of quality of life in acromegaly: no consensus on biochemical parameters. Front Endocrinol 8:40CrossRefGoogle Scholar
  16. 16.
    Kauppinen-Mäkelin R, Sane T, Sintonen H, Markkanen H, Välimäki MJ, Löyttyniemi E, Stenman UH (2006) Quality of life in treated patients with acromegaly. J Clin Endocrinol Metab 91(10):3891–3896CrossRefPubMedGoogle Scholar
  17. 17.
    Matta MP, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P (2008) Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol 158(3):305–310CrossRefPubMedGoogle Scholar
  18. 18.
    Bonapart IE, van Domburg R, ten Have SM, de Herder WW, Erdman RA, Janssen JA, van der Lely AJ (2005) The ‘bio-assay’quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations. Eur J Endocrinol 152(2):217–224CrossRefPubMedGoogle Scholar
  19. 19.
    Shan S, Fang L, Huang J, Chan RCK, Jia G, Wan W (2017) Evidence of dysexecutive syndrome in patients with acromegaly. Pituitary 20(6):661–667CrossRefPubMedGoogle Scholar
  20. 20.
    Leon-Carrion J, Martin-Rodriguez JF, Madrazo-Atutxa A, Soto-Moreno A, Venegas-Moreno E, Torres-Vela E, Benito-López P, Gálvez MA, Tinahones FJ, Leal-Cerro A (2010) Evidence of cogniitve and neurophysiological impairment in patientswith untreated naive acromegaly. J Clin Endocrinol Metab 95(9):4367–4379CrossRefPubMedGoogle Scholar
  21. 21.
    Mattoo SK, Bhansali AK, Gupta N, Grover S, Malhotra R (2008) Psychosocial morbidity in acromegaly: a study from India. Endocrine 34(1–3):17–22CrossRefPubMedGoogle Scholar
  22. 22.
    Leistner SM, Klotsche J, Dimopoulou C, Athanasoulia AP, Roemmler-Zehrer J, Pieper L, Sievers C (2015) Reduced sleep quality and depression associate with decreased quality of life in patients with pituitary adenomas. Eur J Endocrinol 172(6):733–743CrossRefPubMedGoogle Scholar
  23. 23.
    Pereira AM, Tiemensma J, Romijn JA, Biermasz NR (2012) Cognitive impairment and psychopathology in patients with pituitary diseases. Neth J Med 70(6):255–260PubMedGoogle Scholar
  24. 24.
    Kyriakakis N, Lynch J, Gilbey SG, Webb SM (2017) Impaired quality of life in patients with treated acromegaly despite log-term biochemically stable disease: results from a 5-years prospective study. Clin Endocrinol 86(6):806–815CrossRefGoogle Scholar
  25. 25.
    Geraedts VJ, Dimopoulou C, Auer M, Schopohl J, Stalla GK, Sievers C (2014) Health outcomes in acromegaly: depression and anxiety are promising targets for improving reduced quality of life. Front Endocrinol 5:229Google Scholar
  26. 26.
    Webb SM, Badia X (2006) Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. Eur J Endocrinol 155(2):269–277CrossRefPubMedGoogle Scholar
  27. 27.
    Beck AT (1963) Thinking and depression—I—Idiosyncratic content and cognitive distortions. Arch Gen Psychiatry 9:324–333CrossRefPubMedGoogle Scholar
  28. 28.
    Beck AT, Knapp P (2008) Cognitive therapy: foundations, conceptual models, applications and research. Rev Bras Psiquiatr 30(Supl II):S54–S64PubMedGoogle Scholar
  29. 29.
    Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S (2011) Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 14(3):284–294CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Himle JA, Rassi S, Haghigthatgou H, Krone KP, Nesse RM, Abelson J (2001) Group behavioral therapy of obsessive-compulsive disorder: seven-vs. twelve-week outcomes. Depress Anxiety 13(4):161–165CrossRefPubMedGoogle Scholar
  31. 31.
    Crespo I, Santos A, Valassi E, Pires P, Webb SM, Resmini E (2015) Impaired decision making and delayed memory are related with anxiety and depressive symptoms in acromegaly. Endocrine 50(3):756–763CrossRefPubMedGoogle Scholar
  32. 32.
    Powell VB, Abreu N, Oliveira IR, Sudak D (2008) Cognitive-behavioral therapy for depression. Rev Bras Psiquiatr 30(2):73–80CrossRefGoogle Scholar
  33. 33.
    Fava GA, Ruini C, Rafanelli C, Finos L, Conti S, Grandi S (2004) Six-years outcome of cognitive beraviour therapy prevention of recurrent depression. Am J Psychiatry 161(10):1872–1876CrossRefPubMedGoogle Scholar
  34. 34.
    Padesky CA (1994) Schema change processes in cognitive therapy. Clin Psychol Psychother 1(5):267–278CrossRefGoogle Scholar
  35. 35.
    de Almeida AM, Lotufo Neto F (2003) Revisão sobre o uso da terapia cognitiva-comportamental na prevenção de recaídas e recorrências depressivas. Rev Bras Psiquiatr 25(4):239–244CrossRefPubMedGoogle Scholar
  36. 36.
    Hofmann SG, Asnaani A, Vonk IJJ, Sawyer AT, Fang A (2012) The efficacy of cognitive behavioral therapy: a review of meta-analyses. Cognit Ther Res 36(5):427–440CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Ciconelli RM, Ferraz MB, Santos W, Meinão I, Quaresma MR (1999) Tradução para a língua portuguesa e validação do questionário genérico de avaliação de qualidade de vida SF-36 (Brasil SF-36). Rev Bras Reumatol 39(3):143–150Google Scholar
  38. 38.
    Kobak KA, Rock AL, Greist JH (1995) Group behavior therapy for obsessive-compulsive disorder. J Spec Group Work 20(1):26–32CrossRefGoogle Scholar
  39. 39.
    Ferreira de Lima MCGP, Kunzler LS (2017) Terapia cognitivo-comportamental nas doenças reumáticas. Capital Reum 19(3):14–19Google Scholar
  40. 40.
    Kunzler LS, Araujo TCCF (2013) Cognitive therapy: using a specific technique to improve quality of life and health. Estud Psicol 30(2):267–274.  https://doi.org/10.1590/S0103-166X2013000200013 Google Scholar
  41. 41.
    Cunha JA (2001) Manual da versão em Português das Escalas Beck. Casa do Psicólogo, São PauloGoogle Scholar
  42. 42.
    IV Diretrizes Brasileiras de Hipertensão Arterial (2004) Arq Bras Cardiol 82(Supl 4):7–22Google Scholar
  43. 43.
    The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Folllow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3167CrossRefGoogle Scholar
  44. 44.
    Laguardia J, Campos MR, Travassos C, Najar AL, dos Anjos LA, Vasconcelos MM (2013) Dados normativos brasileiros do questionário Short Form-36 versão 2. Rev Bras Epidemiol 16(4):889–897CrossRefPubMedGoogle Scholar
  45. 45.
    Gibbons J, Chakraborti S (2011) Nonparametric statistical inference, 5 edn. Taylor & Francis, New YorkGoogle Scholar
  46. 46.
    Cohen J (1962) The statistical power of abnormal-social psychological research: a review. J Abnorm Soc Psychol 65(3):145–153CrossRefPubMedGoogle Scholar
  47. 47.
    Wild J, Hackmann A, Clark DM (2007) When the present visits the past: updating traumatic memories in social phobia. J Behav Ther Exp Psychiatry 38(4):386–401CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    McManus F, Peerbhoy D, Clark DM (2010) Learning to change a way of being: an interpretative phenomenological perspective on cognitive therapy for social phobia. J Anxiety Disord 24(6):581–589CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Bechara A (2004) The role of emotion in decision-making: evidence from neurological patients with orbital damage. Brain Cogn 55(1):30–40CrossRefPubMedGoogle Scholar
  50. 50.
    Butler G, Hope T (2007) Managing your mind: the mental fitness guide, 2nd edn. Oxford University Press, New YorkGoogle Scholar
  51. 51.
    Luty SE, Carter JD, McKenzie JM, Rae AM, Framptom CMA, Mulder RT, Joyce PR (2007) Randomised controlled trial OS interpersonal psychotherapy and cognitive-behavioural therapy for depression. Br J Psychiatry 190(6):496–502CrossRefPubMedGoogle Scholar
  52. 52.
    Fujio S, Arimura H, Hirano H, Habu M, Bohara M, Moinuddin FM, Kinoshita Y, Arita K (2017) Changes in quality of life in patients with acromegaly after surgical remission—a prospective study using SF-36 questionnaire. Endocrine J 64(1):27–38CrossRefGoogle Scholar
  53. 53.
    Postma MK, Netea-Maier RT, Van den Bergh G, Homan J, Sluiter WJ, Wagenmakers MA, van den Bergh ACM, Wolffenbuttel BHR, Hermus ARM (2012) Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly. Eur J Endocrinol 166:585–592CrossRefPubMedGoogle Scholar
  54. 54.
    Mangupli R, Camperos P, Webb SM (2014) Biochemical and quality of life responses to octreotide-LAR in acromegaly. Pituitary 17(6):495–499CrossRefPubMedGoogle Scholar
  55. 55.
    Yoshida K, Fukuoka H, Matsumoto R, Bando H, Suda K, Nishizawa H, Takahashi Y (2015) The quality of life in acromegalic patients with biochemical remission by surgery alone is superior to that in those with pharmaceutical therapy without radiotherapy, using the newly developed Japanese version of the AcroQoL. Pituitary 18(6):876–883CrossRefPubMedGoogle Scholar
  56. 56.
    Neggers SJCMM, Van Aken MO, De Herder WW, Feelders RA, Janssen JAMJL, Badia X, van der Lely AJ (2008) Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 93(10):3853–3859CrossRefPubMedGoogle Scholar
  57. 57.
    Caron PJ, Bevan JS, Petersenn S, Houchard A, Sert C, Webb SM (2016) Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. Pituitary 19(2):149–157CrossRefPubMedGoogle Scholar
  58. 58.
    Chin SO, Chung CH, Kim SW (2015) Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQol in Korea. BMJ Open 5(6):e006898CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Vilar L, Abucham J, Albuquerque JL, Araujo LA, Azevedo MF, Boguszewski CL, Casulari LA, Cunha Neto MBC, Czepielewski MA, Duarte FHG, Faria MS, Gadelha MR, Garmes HM, Glezer A, Gurgel MH, Jallad RS, Miranda PAC, Montenegro RM, Musolino NRC, Naves LA, Oliveira Júnior AR, Silva CMS, Viecceli C, Bronstein MD (2018) Controversial issues in the management of hyperprolactinemia and prolactinomas—an overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol MetabGoogle Scholar
  60. 60.
    Passos KE (2013) Avaliação do perfil psicopatológico e da qualidade de vida em pacientes acromegálicos [Dissertation]. Brasília: Universidade de BrasíliaGoogle Scholar
  61. 61.
    Sá AMG (2017) Fatores associados com a qualidade de vida e avaliação dos sintomas de ansiedade e depression dos pacientes acromegálicos [Thesis]. São Luis: Universidade Federal do MaranhãoGoogle Scholar
  62. 62.
    Rodrigues de Paula F, Teixeira-Salmela LF, Faria CDCM, Brito PR, Cardoso F (2006) Impact of an exercise program on physical, emotional, and social aspects of quality of life of individuals with Parkinson’s disease. Mov Disord 21(8):1073–1077CrossRefPubMedGoogle Scholar
  63. 63.
    Faria CD, Teixeira-Salmela LF, Nascimento VB, Costa AP, Brito ND, Rodrigues-De-Paula F (2011) Comparisons between the Nottingham Health Profile and the Short Form-36 for assessing the quality of life of community-dwelling elderly. Braz J Phys Ther 15(5):399–405CrossRefGoogle Scholar
  64. 64.
    Lim JB, Chou AC, Yeo W, Lo NN, Chia SL, Chin PL, Yeo SJ (2015) Comparison of patient quality of life scores and satisfaction after common orthopedic surgical interventions. Eur J Orthop Surg Traumatol 25:1007–1012CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Lia Silvia Kunzler
    • 1
  • Luciana Ansaneli Naves
    • 1
  • Luiz Augusto Casulari
    • 1
  1. 1.SRTVS 701BrasíliaBrazil

Personalised recommendations